Array Biopharma (ARRY) Tops Q3 EPS by 11c
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $8.31 -2.69%
Revenue Growth %: -11.6%
Financial Fact:
Loss from operations: -24M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: -11.6%
Financial Fact:
Loss from operations: -24M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q3 EPS of ($0.11), $0.11 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $66.4 million versus the consensus estimate of $31.67 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- AeroVironment restates quarterly financials, citing $89M goodwill error
- ARRAY Technologies Launches DuraTrack D2S™ Tracker, Bringing Differentiated Features of ARRAY’s Trusted DuraTrack System to Dual Row Format Internationally
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
